BioInvent International AB

📍 Lund, Sweden👥 132 employees💰 Last funded May 2017
Biotechnology🌐 bioinvent.com
Website LinkedIn
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in BioInvent International AB?
BioInvent International AB has 1 investors on record on gritt.io.
When did BioInvent International AB last raise funding?
The most recent investment in BioInvent International AB recorded on gritt.io was in May 2017.
What industry is BioInvent International AB in?
BioInvent International AB operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is BioInvent International AB based?
BioInvent International AB is headquartered in Lund, Sweden.